Pakistan and China Sign $850 Million in Pharmaceutical Cooperation Deals
Pakistan and Chinese companies signed agreements worth $850 million at the Pakistan-China Pharmaceutical and Healthcare B2B Investment Conference in Islamabad on July 17-18. The deals include 16 contracts and 80 memoranda of understanding covering vaccine production, active pharmaceutical ingredients (API), medical devices, clinical trials, and generic injectables. Pakistan currently imports all 13 vaccines under its national immunization program and 95% of the API needed for domestic medicine production, making its healthcare system vulnerable to global disruptions. The agreements aim to establish local manufacturing through joint ventures, technology transfer, and plants in CPEC special economic zones. Pakistan has also approved a National Local Vaccine Production Policy to reduce import dependency, which costs hundreds of millions annually and is projected to reach $1.2 billion by 2030. This marks the first substantial Chinese investment in Pakistan's pharmaceutical sector with full government backing.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection